Cargando…

PB2305: EFGARTIGIMOD: CLINICAL DEVELOPMENT OF A NOVEL FCRN ANTAGONIST IN THE TREATMENT OF AUTOIMMUNE DISEASES

Detalles Bibliográficos
Autores principales:	Knoebl, P., de Haard, H., Parys, W., Ulrichts, P., Rocca, F., Guglietta, A., Ayguasanosa, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429708/ http://dx.doi.org/10.1097/01.HS9.0000852048.36167.63

Ejemplares similares

Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia
por: Newland, Adrian C., et al.
Publicado: (2019)

Roles of FcRn in Antigen-Presenting Cells during Autoimmunity and a Clinical Evaluation of Efgartigimod as an FcRn Blocker
por: Zhou, Yihan, et al.
Publicado: (2023)

Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus?
por: Zakrzewicz, Anna, et al.
Publicado: (2022)

PB2667: AUTOIMMUNE DISEASES REVEALED BY SPLANCHNIC THROMBOSIS
por: Laabichi, Amine, et al.
Publicado: (2023)

PB2231: AN OVERLOOKED MIMIC? AUTOIMMUNE MYELOFIBROSIS - A SCOPING REVIEW OF THE LITERATURE
por: Riazat-Kesh, Yosef Joseph Rene Amel, et al.
Publicado: (2023)

PB2242: MANAGEMENT OF AUTOIMMUNE HEMOLYTIC ANEMIA.RETROSPECTIVE STUDY OF A SINGLE CENTER
por: Hortensia-Marioara, I., et al.
Publicado: (2022)

PB2557: CHARACTERISTICS OF AUTOIMMUNE HEMOLYTIC ANEMIA IN ADULTS: A CASE SERIES OF 35 PATIENTS
por: Hanani, Hind, et al.
Publicado: (2023)

PB2249: ATYPICAL CHRONIC MYELOID LEUKEMIA (ACML) AND AUTOIMMUNE DISEASE: REPORT OF TWO CASES.
por: Tatarelli, Caterina, et al.
Publicado: (2023)

Correction: Zakrzewicz et al. Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus? Cells 2022, 11, 942
por: Zakrzewicz, Anna, et al.
Publicado: (2022)

PB2360: QUALITY OF LIFE AND TREATMENT SATISFACTION AMONG PATIENTS UNDER LONG-TERM ANTICOAGULANT THERAPY WITH VITAMIN K ANTAGONISTS
por: Varaklioti, A., et al.
Publicado: (2022)

PB2561: DEVELOPMENT OF COLD AGGLUTININ AUTOIMMUNE HEMOLYTIC ANEMIA DURING TREATMENT FOR PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: A CASE REPORT.
por: Haddad, Nabila, et al.
Publicado: (2023)

PB2459: AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES OF HAEMATOLOGIC MALIGNANCIES COMPLICATED BY AUTOIMMUNE DISEASES
por: Kang, Ying, et al.
Publicado: (2023)

PB1779: DEVELOPING NOVEL SYNERGISTIC DRUG COMBINATIONS WITH VENETOCLAX IN ACUTE MYELOID LEUKAEMIA
por: Harrigan, R., et al.
Publicado: (2022)

PB2241: CHARACTERISTICS AND OUTCOME OF WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA) IN ADULTS: A RETROSPECTIVE ANALYSIS OF 110 TUNISIAN PATIENTS
por: Bouslama, E., et al.
Publicado: (2022)

PB2168: P27: A NOVEL SUBSTRATE OF PDGFR
por: Giron, Carlos Miguel Castillo, et al.
Publicado: (2023)

PB2362: BEST PRACTICES ON EMPOWERING AND INVOLVING PATIENTS LIVING WITH HEMATOLOGICAL MALIGNANCIES ON THE DEVELOPMENT OF NOVEL PATIENT-REPORTED OUTCOME MEASURES
por: Vrontaras, N., et al.
Publicado: (2022)

PB1822: A CASE OF EXTRAMEDULLARY ACUTE MYELOID LEUKEMIA SUCCESSFULLY TREATED WITH NOVEL AGENTS
por: Gianfelici, V., et al.
Publicado: (2022)

PB2202: NOVEL PREDICTORS FOR VENOUS AND ARTERIAL THROMBOSIS IN POLYCYTHEMIA VERA
por: Ivanović, Jelena, et al.
Publicado: (2023)

PB1923: NON-HEMATOLOGIC AUTOIMMUNE DISORDERS IN CLL: PREVALENCE AND PROGNOSTIC IMPACT IN A REAL-LIFE COHORT FROM A SINGLE-CENTRE
por: De Tomás, Miguel Argüello, et al.
Publicado: (2023)

PB1848: NGS AS A FUNDAMENTAL TOOL FOR THE DEVELOPMENT OF NEW TARGETED THERAPIES
por: Velarde, P., et al.
Publicado: (2022)

PB2163: SCREENING FOR SUSPECTED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME (ALPS) PATIENTS IN CHILDREN WITH CHRONIC CYTOPENIAS AND NON-MALIGNANT LYMPHADENOPATHY: A STEP FOR BETTER STRATIFICATION.
por: Saleh, L., et al.
Publicado: (2022)

Efgartigimod: First Approval
por: Heo, Young-A
Publicado: (2022)

PB2201: THYMUS DEVELOPMENT IN CONGENITAL HEART DISEASES
por: Bódi, I., et al.
Publicado: (2022)

PB1703: MODELING T-CELL DEVELOPMENT AND T-ALL INITIATION
por: Dick, Advaita M, et al.
Publicado: (2023)

PB2644: NOVEL GLOBAL FIBRINOLYSIS CAPACITY ASSAYS: THE NEXT STEP IN FIBRINOLYSIS SCREENING?
por: Evenepoel, Anton, et al.
Publicado: (2023)

PB1827: ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
por: Marques, I., et al.
Publicado: (2022)

PB2155: B-CELL NON-HODGKIN’S LYMPHOMAS ASSOCIATED WITH AMYLOIDOSIS
por: Navrátilova, M., et al.
Publicado: (2022)

PB2550: EXPLORATION OF B-CELL RECEPTOR AND T-CELL RECEPTOR REPERTOIRES REVEALS DISTINCT MECHANISMS IN PURE RED CELL APLASIA, AUTOIMMUNE HEMOLYTIC ANEMIA AND APLASTIC ANEMIA
por: Zhang, Ruoxi, et al.
Publicado: (2023)

PB2327: BONE MARROW STUDY IN THROMBOPENIA
por: López De Ugarriza, P., et al.
Publicado: (2022)

PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION
por: Dale, D. C., et al.
Publicado: (2022)

PB2351: ANXIETY AT THE HEMATOLOGIST
por: Trojan, S., et al.
Publicado: (2022)

PB1952: CLL IN AYA
por: Mohamed, Shehab, et al.
Publicado: (2023)

PB2344: RESILIENCE IN PATIENTS WITH LYMPHOID MALIGNANCIES: THE REPLY STUDY.
por: Dos Santos, G., et al.
Publicado: (2022)

PB2642: EVALUATION OF INNOVATIVE LABORATORY TESTS TO PREDICT A THROMBOTIC PHENOTYPE IN A FAMILY WITH DYSFIBRINOGENEMIA AND A NOVEL FGG MUTATION.
por: Monard, Amaury, et al.
Publicado: (2023)

PB1859: DEFINING T-CELL POPULATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA
por: Mora, A., et al.
Publicado: (2022)

PB1754: TELOMERE LENGTH IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
por: Vakonaki, E., et al.
Publicado: (2022)

PB2075: CRYSTAL STORING HISTIOCYTOSIS PRESENTING AS HEAD AND NECK TUMORS
por: De La Flor Weiss, E. P., et al.
Publicado: (2022)

PB2030: CLINICAL, LABORATORY PROFILE, TREATMENT AND OUTCOME OF PRIMARY AMYLOIDOSIS IN THE ERA OF NOVEL AGENTS: AN EXPERIENCE FROM A TERTIARY CARE HOSPITAL IN INDIA
por: Sivaprakasam, Y., et al.
Publicado: (2022)

PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4)
por: Broome, Catherine M, et al.
Publicado: (2023)

PB1882: BONE MARROW LYMPHOCYTES AND SUBPOPULATION: A NOVEL PROGNOSTIC INDICATOR IN ACUTE MYELOID LEUKEMIA
por: Ibrahim, Nahla
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kpotdjtgmkv4bjubel75oed9dc